Microbia Announces Second Collaboration Agreement with Ranbaxy Laboratories
News Nov 02, 2005
Microbia, Inc. have announced that its Precision Engineering™ business unit has entered into a research collaboration with Ranbaxy Laboratories to lower the cost of a biomanufacturing process under development by Ranbaxy.
The goal is to achieve a greater than 100 percent productivity improvement in the precommercial biomanufacturing of an undisclosed pharmaceutical product.
Microbia will undertake strain engineering and laboratory-scale testing. Ranbaxy assumes responsibility for optimizing processes and validating product specification acceptability.
Under the agreement, Ranbaxy will fund Microbia's research and development and will make payments based on the achievement of development milestones. Financial terms were not disclosed.
This is the second agreement between the two companies, following a successful collaboration to apply Precision Engineering™ to generate higher yields in a Ranbaxy biomanufacturing process for a statin.
Ranbaxy has since advanced the improved strain into commercial manufacturing. The two companies have collaborated to improve biomanufacturing processes since February 2003.
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
GE Focuses Portfolio for Growth and Shareholder Value CreationNews
Healthcare to become standalone company; GE expects to monetize 20% and distribute remaining 80% of GE Healthcare to shareholders tax-free.READ MORE